319 related articles for article (PubMed ID: 19929209)
1. The utility of rat jejunal permeability for biopharmaceutics classification system.
Zakeri-Milani P; Valizadeh H; Tajerzadeh H; Islambulchilar Z
Drug Dev Ind Pharm; 2009 Dec; 35(12):1496-502. PubMed ID: 19929209
[TBL] [Abstract][Full Text] [Related]
2. Biopharmaceutical classification of drugs using intrinsic dissolution rate (IDR) and rat intestinal permeability.
Zakeri-Milani P; Barzegar-Jalali M; Azimi M; Valizadeh H
Eur J Pharm Biopharm; 2009 Sep; 73(1):102-6. PubMed ID: 19442726
[TBL] [Abstract][Full Text] [Related]
3. The suitability of an in situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests.
Kim JS; Mitchell S; Kijek P; Tsume Y; Hilfinger J; Amidon GL
Mol Pharm; 2006; 3(6):686-94. PubMed ID: 17140256
[TBL] [Abstract][Full Text] [Related]
4. Assessment of intestinal absorption of vitexin-2''-o-rhamnoside in hawthorn leaves flavonoids in rat using in situ and in vitro absorption models.
Xu YA; Fan G; Gao S; Hong Z
Drug Dev Ind Pharm; 2008 Feb; 34(2):164-70. PubMed ID: 18302035
[TBL] [Abstract][Full Text] [Related]
5. Prediction of human absorption of a trioxane antimalarial drug (CDRI 99/411) using an in-house validated in situ single-pass intestinal perfusion model.
Wahajuddin ; Singh SP; Patel K; Pradhan T; Siddiqui HH; Singh SK
Arzneimittelforschung; 2011; 61(9):532-7. PubMed ID: 22029231
[TBL] [Abstract][Full Text] [Related]
6. Segmental-dependent membrane permeability along the intestine following oral drug administration: Evaluation of a triple single-pass intestinal perfusion (TSPIP) approach in the rat.
Dahan A; West BT; Amidon GL
Eur J Pharm Sci; 2009 Feb; 36(2-3):320-9. PubMed ID: 19028572
[TBL] [Abstract][Full Text] [Related]
7. An improved prediction of the human in vivo intestinal permeability and BCS class of drugs using the in vitro permeability ratio obtained for rat intestine using an Ussing chamber system.
Li H; Jin HE; Shim WS; Shim CK
Drug Dev Ind Pharm; 2013 Oct; 39(10):1515-22. PubMed ID: 22934579
[TBL] [Abstract][Full Text] [Related]
8. Biopharmaceutics classification and intestinal absorption study of apigenin.
Zhang J; Liu D; Huang Y; Gao Y; Qian S
Int J Pharm; 2012 Oct; 436(1-2):311-7. PubMed ID: 22796171
[TBL] [Abstract][Full Text] [Related]
9. Quantitative biopharmaceutics classification system: the central role of dose/solubility ratio.
Rinaki E; Valsami G; Macheras P
Pharm Res; 2003 Dec; 20(12):1917-25. PubMed ID: 14725354
[TBL] [Abstract][Full Text] [Related]
10. Biopharmaceutics classification of puerarin and comparison of perfusion approaches in rats.
Li H; Dong L; Liu Y; Wang G; Wang G; Qiao Y
Int J Pharm; 2014 May; 466(1-2):133-8. PubMed ID: 24607203
[TBL] [Abstract][Full Text] [Related]
11. Predicting human intestinal permeability using single-pass intestinal perfusion in rat.
Zakeri-Milani P; Valizadeh H; Tajerzadeh H; Azarmi Y; Islambolchilar Z; Barzegar S; Barzegar-Jalali M
J Pharm Pharm Sci; 2007; 10(3):368-79. PubMed ID: 17727800
[TBL] [Abstract][Full Text] [Related]
12. Regional intestinal drug permeation: biopharmaceutics and drug development.
Lennernäs H
Eur J Pharm Sci; 2014 Jun; 57():333-41. PubMed ID: 23988845
[TBL] [Abstract][Full Text] [Related]
13. Single-pass intestinal perfusion to establish the intestinal permeability of model drugs in mouse.
Escribano E; Sala XG; Salamanca J; Navarro CR; Regué JQ
Int J Pharm; 2012 Oct; 436(1-2):472-7. PubMed ID: 22814225
[TBL] [Abstract][Full Text] [Related]
14. Human intestinal permeability.
Lennernäs H
J Pharm Sci; 1998 Apr; 87(4):403-10. PubMed ID: 9548891
[TBL] [Abstract][Full Text] [Related]
15. Provisional biopharmaceutical classification of some common herbs used in Western medicine.
Waldmann S; Almukainzi M; Bou-Chacra NA; Amidon GL; Lee BJ; Feng J; Kanfer I; Zuo JZ; Wei H; Bolger MB; Löbenberg R
Mol Pharm; 2012 Apr; 9(4):815-22. PubMed ID: 22352942
[TBL] [Abstract][Full Text] [Related]
16. Correlation between epithelial cell permeability of cephalexin and expression of intestinal oligopeptide transporter.
Chu XY; Sánchez-Castaño GP; Higaki K; Oh DM; Hsu CP; Amidon GL
J Pharmacol Exp Ther; 2001 Nov; 299(2):575-82. PubMed ID: 11602669
[TBL] [Abstract][Full Text] [Related]
17. Biopharmaceutics classification systems for new molecular entities (BCS-NMEs) and marketed drugs (BCS-MD): theoretical basis and practical examples.
Papadopoulou V; Valsami G; Dokoumetzidis A; Macheras P
Int J Pharm; 2008 Sep; 361(1-2):70-7. PubMed ID: 18614303
[TBL] [Abstract][Full Text] [Related]
18. Repeated oral rifampicin decreases the jejunal permeability of R/S-verapamil in rats.
Sandström R; Lennernäs H
Drug Metab Dispos; 1999 Aug; 27(8):951-5. PubMed ID: 10421625
[TBL] [Abstract][Full Text] [Related]
19. Intestinal permeability and its relevance for absorption and elimination.
Lennernäs H
Xenobiotica; 2007; 37(10-11):1015-51. PubMed ID: 17968735
[TBL] [Abstract][Full Text] [Related]
20. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.
Winiwarter S; Bonham NM; Ax F; Hallberg A; Lennernäs H; Karlén A
J Med Chem; 1998 Dec; 41(25):4939-49. PubMed ID: 9836611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
